Conditions: Diabetes Mellitus, Type 1 Diabetes Mellitus, Type 2
Allocation: RANDOMIZED | Intervention model: CROSSOVER
Enrollment: 12
Healthy volunteers: no

Brief summary:
This study will investigate how the body processes nasal glucagon and the effect of nasal glucagon on the body. After an 8-hour overnight fast and 4 hours after the start of a low-carbohydrate breakfast, the study drug will be delivered into the participant's nostril(s) (intranasally) once or twice in each of four study periods. The study is open to adults with type 1 or type 2 diabetes and is expected to last about 50 days for each participant.

Detailed description:

Arms:
arm 1: Treatment 1, single nasal glucagon (NG) dose of 3 milligram (mg). arm 2: Treatment 2, NG dose of 3 mg plus 3 mg NG dose in same nostril 15 minutes later. arm 3: Treatment 3, NG dose of 3 mg plus 3 mg NG dose in the opposite nostril 15 minutes later. arm 4: Treatment 4, NG dose of 3 mg then immediately 3 mg NG dose in the opposite nostril.

Interventions: intervention 1: Nasal Glucagon
Intervention descriptions: intervention 1: Administered intranasally.

Protocol document: